Search

everythinglearnresearchcommunity

for

Search:↓

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

A parasite molecule can speed up skin healing and reduce scarring.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Monocyte-derived dendritic cells play a key role in UVB-induced skin sensitivity and inflammation.

Dihydrotestosterone boosts inflammation in fat cells more than testosterone.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

Upadacitinib improved multiple immune-related conditions in one patient.

Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.

Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

P311 helps skin stem cells become myofibroblast-like cells, aiding wound healing.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

TNF-alpha inhibitors can cause various immune-related skin issues.

RANKL causes lymph nodes to grow by making certain cells multiply.

Regulatory T cells and mesenchymal stem cells work together to prevent immune system overreactions and tissue damage.

A(1-7) treatment reduces symptoms of lupus in mice.

Innate lymphoid cells type 1 may contribute to alopecia areata.

Belatacept may be a promising treatment for alopecia areata.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.

Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Certain genetic markers can indicate higher or lower risk for systemic lupus erythematosus.